Vacunación frente a la neumonía adquirida en la comunidad del adultoactualización 2018 del posicionamiento del Grupo de Neumoexpertos en Prevención

  1. E. Redondo 1
  2. I. Rivero-Calle 2
  3. D.A. Vargas 3
  4. E. Mascarós 4
  5. J.L. Díaz-Maroto 5
  6. M. Linares 6
  7. Á. Gil 7
  8. J. Molina 8
  9. I. Jimeno 9
  10. D. Ocaña 10
  11. J.E. Yuste 11
  12. F. Martinón-Torres 2
  1. 1 Centro de Salud Internacional Ayuntamiento de Madrid, Madrid, España
  2. 2 Complexo Hospitalario Universitario de Santiago
    info

    Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, España

    ROR https://ror.org/00mpdg388

  3. 3 Hospital de Poniente, Almería, España
  4. 4 Centro de Atención Primaria Fuente de San Luís, Valencia, España
  5. 5 Centro de Atención Primaria de Guadalajara, Guadalajara, España
  6. 6 Fundación io, Madrid, España
  7. 7 Universidad Rey Juan Carlos, Madrid, España
  8. 8 Centro de Atención Primaria Francia, Fuenlabrada, Madrid, España
  9. 9 Centro de salud Isla de Oza, Madrid, España
  10. 10 Centro de Atención Primaria Algeciras-Norte, Algeciras, Cádiz, España
  11. 11 Centro Nacional de Microbiología, Instituto de Salud Carlos III
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2018

Número: 8

Páxinas: 590-597

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2018.09.005 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Obxectivos de Desenvolvemento Sustentable

Resumo

La neumonía adquirida en la comunidad (NAC) continúa siendo una causa importante de morbimortalidad en adultos. El objetivo de este documento es actualizar la guía práctica de prevención de la NAC mediante vacunación en España desarrollada en 2016 en función de las vacunas y evidencias disponibles mediante revisión bibliográfica y opinión de expertos. Las vacunas frente al neumococo y la gripe continúan siendo las principales herramientas preventivas disponibles frente a la NAC, y pueden contribuir a disminuir la carga de enfermedad por NAC y sus complicaciones asociadas. La evidencia disponible avala las indicaciones prioritarias establecidas en esta guía, y sería recomendable tratar de lograr una difusión e implementación amplia en la práctica clínica rutinaria de estas recomendaciones.

Referencias bibliográficas

  • E. Redondo, I. Rivero, D.A. Vargas, E. Mascaros, J.L. Diaz-Maroto, M. Linares, et al. Vacunación frente a la neumonía adquirida en la comunidad del adulto. Posicionamiento del Grupo de Neumoexpertos en Prevención Semergen, 42 (2016), pp. 464-475 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • Y. Wang, J. Li, Y. Wang, W. Gu, F. Zhu Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations Hum Vaccin Immunother., 14 (2018), pp. 1003-1012 CrossRefView Record in ScopusGoogle Scholar
  • S. Moberley, P.V. Licciardi, A. Balloch, R. Andrews, A.J. Leach, M. Kirkwood, et al. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness Vaccine., 35 (2017), pp. 2908-2915 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • I. Papadatou, V. Spoulou Pneumococcal vaccination in high-risk individuals: Are we doing it right? Clin Vaccine Immunol., 23 (2016), pp. 388-395 View Record in ScopusGoogle Scholar
  • N.J. Andrews, P.A. Waight, R.C. George, M.P. Slack, E. Miller Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales Vaccine., 30 (2012), pp. 6802-6808 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Schiffner-Rohe, A. Witt, J. Hemmerling, C. von Eiff, F.W. Leverkus Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk — a systematic review and meta-analysis PLoS One., 11 (2016), p. e0146338 CrossRefView Record in ScopusGoogle Scholar
  • G. Falkenhorst, C. Remschmidt, T. Harder, E. Hummers-Pradier, O. Wichmann, C. Bogdan Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: Systematic review and meta-analysis PLoS One., 12 (2017), p. e0169368 CrossRefView Record in ScopusGoogle Scholar
  • M. Tin Tin Htar, A.L. Stuurman, G. Ferreira, C. Alicino, K. Bollaerts, C. Paganino, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies PLoS One., 12 (2017), p. e0177985 CrossRefGoogle Scholar
  • T. Maruyama, O. Taguchi, M.S. Niederman, J. Morser, H. Kobayashi, T. Kobayashi, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: Double blind, randomised and placebo controlled trial BMJ., 340 (2010) c1004 Google Scholar
  • J.A. Walters, J.N. Tang, P. Poole, R. Wood-Baker Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease Cochrane Database Syst Rev., 1 (2017), p. CD001390 View Record in ScopusGoogle Scholar
  • J.A. Walters, S. Smith, P. Poole, R.H. Granger, R. Wood-Baker Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease Cochrane Database Syst Rev. (2010) CD001390 Google Scholar
  • J.A. Suaya, Q. Jiang, D.A. Scott, W.C. Gruber, C. Webber, B. Schmoele-Thoma, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults Vaccine., 36 (2018), pp. 1477-1483 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.M. McLaughlin, Q. Jiang, R.E. Isturiz, H.L. Sings, D.L. Swerdlow, B.D. Gessner, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design Clin Infect Dis. (2018), 10.1093/cid/ciy312 Google Scholar
  • A. Vila-Corcoles, O. Ochoa-Gondar, C. de Diego, E. Satue, M. Aragon, A. Vila-Rovira, et al. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: Results from the EPIVAC cohort study BMC Infect Dis., 18 (2018), p. 196 View Record in ScopusGoogle Scholar
  • M.J.M. Bonten, S.M. Huijts, M. Bolkenbaas, C. Webber, S. Patterson, S. Gault, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults N Engl J Med., 372 (2015), pp. 1114-1125 View Record in ScopusGoogle Scholar
  • V. Baldo, S. Cocchio, T. Gallo, P. Furlan, P. Romor, C. Bertoncello, et al. Pneumococcal conjugated vaccine reduces the high mortality for community-acquired pneumonia in the elderly: An Italian regional experience PLoS One., 11 (2016), p. e0166637 CrossRefView Record in ScopusGoogle Scholar
  • G.D. Lopardo, C. Vizzotti, N. Giglio, E. Raimondo, D. Fridman, P. Micone, et al. Effectiveness of PCV 13 vaccine in adults aged 65 and over to prevent community-acquired pneumonia 28th ECCMID 21-24 April, Madrid, Spain (2018) Google Scholar
  • J.M. Figueira-Gonçalves, N. Bethencourt Martín, L.I. Pérez-Méndez, D. Díaz-Pérez, C. Guzmán-Sáenz, P. Viña-Manrique, et al. Impacto de la vacunación neumocócica de polisacáridos conjugados 13-valente en las exacerbaciones de pacientes con enfermedad pulmonar obstructiva crónica con obstrucción al flujo aéreo moderada-muy grave Rev Esp Quimioter., 30 (2017), pp. 269-275 View Record in ScopusGoogle Scholar
  • M.A. Hernandez Mezquita, A. Morales Boscam, V. Hidalgo Sierra, M. Sobrino Ballesteros, M. Barrueco Ferrero Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Eur Respir J., 48 (Suppl 60.) (2016) Google Scholar
  • J.M. Rodriguez Gonzalez-Moro, R. Menendez, M. Campins, N. Lwoff, I. Oyaguez, M. Echave, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain Clin Drug Investig., 36 (2016), pp. 41-53 CrossRefView Record in ScopusGoogle Scholar
  • S.M. Huijts, C.H. van Werkhoven, M. Bolkenbaas, D.E. Grobbee, M.J.M. Bonten Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly Vaccine., 35 (2017), pp. 4444-4449 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.A. Ramirez, T.L. Wiemken, P. Peyrani, F.W. Arnold, R. Kelley, W.A. Mattingly, et al. Adults hospitalized with pneumonia in the United States: Incidence, epidemiology, and mortality Clin Infect Dis., 65 (2017), pp. 1806-1812 View Record in ScopusGoogle Scholar
  • F. González-Romo, A. García Rojas, M. Labrador Horrillo, V. Barrios, M.C. Magro, P. Gil Consenso sobre la vacunación anti-neumocócica en el adulto por riesgo de edad y patología de base. Actualización 2017 Rev Esp Quimioter., 30 (2017), pp. 142-168 View Record in ScopusGoogle Scholar
  • A. Cassini, E. Colzani, A. Pini, M.J. Mangen, D. Plass, S.A. McDonald, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013 Euro Surveill., 23 (2018), pp. 17-00454 View Record in ScopusGoogle Scholar
  • J.M. Rudd, H.K. Ashar, V.T. Chow, N. Teluguakula Lethal synergism between Influenza and Streptococcus pneumoniae J Infect Pulm Dis., 2 (2016), 10.16966/2470-3176.114 Google Scholar
  • J.C. Kwong, K.L. Schwartz, M.A. Campitelli, H. Chung, N.S. Crowcroft, T. Karnauchow, et al. Acute myocardial infarction after laboratory-confirmed Influenza infection N Engl J Med., 378 (2018), pp. 345-353 View Record in ScopusGoogle Scholar
  • V.C. Huber Influenza vaccines: From whole virus preparations to recombinant protein technology Expert Rev Vaccines., 13 (2014), pp. 31-42 CrossRefView Record in ScopusGoogle Scholar
  • R. Ortiz de Lejarazu, S. Tamames [Influenza vaccination. Effectiveness of current vaccines and future challenges] Enferm Infecc Microbiol Clin., 33 (2015), pp. 480-490 ArticleDownload PDFGoogle Scholar
  • P.C. Soema, R. Kompier, J.P. Amorij, G.F.A. Kersten Current and next generation influenza vaccines: Formulation and production strategies Eur J Pharm Biopharm., 94 (2015), pp. 251-263 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.K. Tosh, R.M. Jacobson, G.A. Poland Influenza vaccines: From surveillance through production to protection Mayo Clin Proc., 85 (2010), pp. 257-273 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • S.S. Wong, R.J. Webby Traditional and new influenza vaccines Clin Microbiol Rev., 26 (2013), pp. 476-492 View Record in ScopusGoogle Scholar
  • A. Garcia, R. Ortiz de Lejarazu, J. Reina, D. Callejo, J. Cuervo, R. Morano Larragueta Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain Hum Vaccin Immunother., 12 (2016), pp. 2269-2277 CrossRefView Record in ScopusGoogle Scholar
  • M. Uhart, H. Bricout, E. Clay, N. Largeron Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe Hum Vaccin Immunother., 12 (2016), pp. 2259-2268 CrossRefView Record in ScopusGoogle Scholar
  • A. Perez Rubio, J.M. Eiros Bouza Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España Rev Esp Quimioter., 31 (2018), pp. 43-52 View Record in ScopusGoogle Scholar
  • Public Health England (PHE). Summary of data to support the choice of influenza vaccination for adults in primary care. London: PHE; 2018. Disponible en: https://www.gov.uk/government/publications/flu-vaccination-supporting-data-for-adult-vaccines/summary-of-data-to-support-the-choice-of-influenza-vaccination-for-adults-in-primary-care Google Scholar
  • A. Perez-Rubio, J.M. Eiros Bouza Cell culture-derived flu vaccine: Present and future Hum Vaccin Immunother., 14 (2018), pp. 1874-1882 CrossRefGoogle Scholar
  • C.I. Paules, S.G. Sullivan, K. Subbarao, A.S. Fauci Chasing seasonal influenza — The need for a universal influenza vaccine N Engl J Med., 378 (2018), pp. 7-9 CrossRefView Record in ScopusGoogle Scholar
Fonte de datos: Dialnet